Form 4: United Therapeutics CEO Executes Stock Option Plan

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• Martine Rothblatt, Chairperson and CEO of United Therapeutics, exercised 9,500 stock options at a strike price of $146.03.
• The acquired shares were subsequently sold in multiple transactions on June 11, 2026.
• The sales were executed at weighted average prices ranging from $542.98 to $551.87 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 7, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions are purely administrative and follow a pre-disclosed, systematic trading plan.

Positives

• The transactions were executed under a pre-planned 10b5-1 program, indicating a systematic approach to liquidity rather than reactive selling.
• The CEO maintains a significant remaining beneficial ownership stake in the company, including 40,513 shares held directly and substantial holdings in family trusts.

Negatives

• The transaction results in a reduction of the CEO's direct share ownership following the exercise and sale.

Risks

• The 10b5-1 plan is scheduled to continue until the earlier of the exercise of 1,734,410 options or December 31, 2026, which may lead to ongoing periodic selling pressure.

Future Outlook

The reporting person intends to continue selling shares under the established 10b5-1 plan until the end of 2026 or until the exhaustion of 1,734,410 options.

Industry Context

StockSavvy.ai notes that executive selling under 10b5-1 plans is a standard practice for long-term compensation realization in the biotechnology sector and generally does not signal a lack of confidence in company fundamentals.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives at large-cap biotech firms like Amgen or Gilead to avoid allegations of insider trading.
• The volume of shares sold relative to the CEO's total holdings remains consistent with typical executive diversification strategies.

Related Party Transactions

• The filing discloses holdings in various family trusts where the reporting person or spouse serves as trustee or beneficiary.

Stakeholder Impact

• Minimal impact expected as the sales are pre-planned and systematic.

Next Steps

• Continued execution of the 10b5-1 trading plan through December 31, 2026.

Key Dates

Keywords

United Therapeutics, UTHR, Martine Rothblatt, Insider Trading, Form 4, Stock Options, 10b5-1